Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.

Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.

Toon andere (1) versies

OBJECTIVES: Reports have suggested that a reduction in tumour 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) examination during or after neoadjuvant chemotherapy may predict pathological response in oesophageal cancer. Our aim was to determine whether metabolic response pr...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Gillies, R, Middleton, MR, Blesing, C, Patel, K, Warner, N, Marshall, R, Maynard, N, Bradley, K, Gleeson, F
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2012

Gelijkaardige items

Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer
door: Gillies, R, et al.
Gepubliceerd in: (2012)

Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics.
door: Findlay, J, et al.
Gepubliceerd in: (2017)

Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.
door: Gillies, R, et al.
Gepubliceerd in: (2012)

Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma
door: Gillies, R, et al.
Gepubliceerd in: (2012)

Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
door: Findlay, J, et al.
Gepubliceerd in: (2017)

Tumour expression of the DNA repair protein, XPF, predicts pathological response to neoadjuvant oxaliplatin chemotherapy in oesophageal cancer
door: Gillies, R, et al.
Gepubliceerd in: (2011)

Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer.
door: Gillies, R, et al.
Gepubliceerd in: (2011)

Additional benefit of 18F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer
door: Gillies, R, et al.
Gepubliceerd in: (2010)

Predicting pathological response of esophageal cancer to neoadjuvant chemotherapy: the implications of metabolic nodal response for personalised therapy
door: Findlay, J, et al.
Gepubliceerd in: (2016)

Role of adjuvant radiotherapy following neo-adjuvant chemotherapy (NACT) and surgery in oesophageal cancer - a multi-centre retrospective cohort study
door: Teoh, S, et al.
Gepubliceerd in: (2016)

The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma.
door: Chowdhury, F, et al.
Gepubliceerd in: (2008)

Neoadjuvant chemotherapy for oesophageal carcinoma - a risk factor for postoperative pneumonia?
door: Millo, J, et al.
Gepubliceerd in: (2003)

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
door: Findlay, J, et al.
Gepubliceerd in: (2016)

Survival after curative chemoradiotherapy or neoadjuvant therapy and surgery converges in higher-risk patients with oesophageal cancer
door: Rana, M, et al.
Gepubliceerd in: (2021)

Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro‐oesophageal cancer
door: den Boer, RB, et al.
Gepubliceerd in: (2020)

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
door: John M. Findlay, et al.
Gepubliceerd in: (2016-04-01)

A reply to evidence-based radiation oncology: oesophagus.
door: Gillies, R, et al.
Gepubliceerd in: (2010)

A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma
door: Kieran G. Foley, et al.
Gepubliceerd in: (2021-06-01)

Adjuvant radiotherapy following neo-adjuvant chemotherapy and surgery in oesophageal cancer: a retrospective cohort study of survival
door: Teoh, S, et al.
Gepubliceerd in: (2018)

Assessment of Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Using MRI and 18F FDG PET/CT
door: Reem Yusuf AlBuainain, et al.
Gepubliceerd in: (2025-01-01)

Role of F-18 FDG PET/CT in Predicting Response to Neoadjuvant Chemotherapy in Invasive Ductal Breast Cancer
door: Tarik Sengoz, et al.
Gepubliceerd in: (2023-04-01)

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
door: Han Wonshik, et al.
Gepubliceerd in: (2011-10-01)

PET/CT staging and response evaluation of post-transplantation lymphoproliferative disease (PTLD).
door: Chowdhury, F, et al.
Gepubliceerd in: (2009)

Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy
door: A. G. M. T. Powell, et al.
Gepubliceerd in: (2020-08-01)

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.
door: Alexander M Th Schmitz, et al.
Gepubliceerd in: (2017-01-01)

Direct comparison of PET/CT and MRI to predict the pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis
door: Lihua Chen, et al.
Gepubliceerd in: (2017-08-01)

Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery
door: Findlay, J, et al.
Gepubliceerd in: (2019)

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma
door: Turkington, RC, et al.
Gepubliceerd in: (2019)

Whole transcriptome analysis of breast tumors during neoadjuvant chemotherapy: association with response to preoperative chemotherapy
door: M. K. Ibragimova, et al.
Gepubliceerd in: (2022-03-01)

Clinical value of SUVpeak-to-tumor centroid distance on FDG PET/CT for predicting neoadjuvant chemotherapy response in patients with breast cancer
door: Sun-pyo Hong, et al.
Gepubliceerd in: (2024-10-01)

Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis
door: Sangwon Han, et al.
Gepubliceerd in: (2020-10-01)

Efficacy Of 18FDG-PET/CT In Predicting Response After Neoadjuvant Chemoradiation In Rectal Cancer
door: Narendra Pandit, et al.
Gepubliceerd in: (2023-08-01)

Comparison between body composition parameters and response to neoadjuvant chemotherapy by using pre-treatment PET CT in locally advanced breast cancer
door: Inci Kizildag Yirgin, et al.
Gepubliceerd in: (2020-01-01)

The Role of Pretreatment 18F-FDG PET/CT for Early Prediction of Neoadjuvant Chemotherapy Response in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
door: Yao J, et al.
Gepubliceerd in: (2021-10-01)

Predictors of complete response to neoadjuvant chemotherapy in non-metastatic bladder cancer
door: P. Sousa Passos, et al.
Gepubliceerd in: (2020-11-01)

Whole transcriptome analysis of breast tumors during neoadjuvant chemotherapy: association with response to preoperative chemotherapy. Additional material
door: M. K. Ibragimova, et al.
Gepubliceerd in: (2022-03-01)

Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study
door: Rui-Qin Zhou, et al.
Gepubliceerd in: (2023-05-01)

[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial
door: Giulia Polverari, et al.
Gepubliceerd in: (2020-10-01)

Correlation Between 18F-FDG PET/CT SUVmax and Clinicopathological Features, Neoadjuvant Chemotherapy Response in Invasive Ductal Breast Carcinoma Patients
door: LU Shengnan, et al.
Gepubliceerd in: (2019-02-01)

Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma
door: Willard Wong, et al.
Gepubliceerd in: (2021-07-01)